Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oliceridine versus sufentanil patient-controlled analgesia after unicompartmental knee arthroplasty
ChiCTR2500096012Phase 4Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of oliceridine and sufentanil in postoperative pain (2 arms), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: Pain visual analog scale score. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
oliceridinesufentanil
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2500096012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096012.